A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07304154
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases To determine the recommended dose for Phase 1b. To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Inflammatory Demyelinating Polyneuropathy
- Myasthenia Gravis
- Multiple Sclerosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Kite, A Gilead Company
- Last updated on ClinicalTrials.gov
- August 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Hoag Memorial Hospital Presbyterian · Newport Beach, CA
- Stanford Neuroscience Health Center · Palo Alto, CA
New York · 1
- Columbia University Irving Medical Center · New York, NY
Utah · 1
- LDS Hospital - Intermountain Health · Salt Lake City, UT
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.